Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, as part of its Regulation D 506(c) offering seeking to raise up to $5 million. The funding round is structured to avoid dilution to Quantum BioPharma shareholders, representing a strategic approach to capital raising that protects existing investor value while expanding market opportunities.
The webinar will feature Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius. These industry veterans will discuss the investment opportunity for unbuzzd™, a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. The event will also cover leadership strategy, distribution plans, and include a question-and-answer session.
This development is significant because it represents the commercialization phase of a product with potential implications for public health and wellness markets. The unbuzzd™ beverage addresses alcohol-related concerns that affect millions globally, offering a scientifically backed solution that could transform how consumers approach alcohol consumption and recovery. The involvement of former Celsius CEO Gerry David brings substantial beverage industry expertise to the venture, suggesting strong commercial potential.
Quantum BioPharma retains significant financial interest in Unbuzzd Wellness, holding 20.11% ownership as of March 31, 2025, and receiving royalty payments of 7% of sales until payments total $250 million, after which the royalty decreases to 3% in perpetuity. This arrangement provides Quantum BioPharma with ongoing revenue streams while allowing focused development of pharmaceutical applications through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
The company maintains 100% rights to develop similar products for pharmaceutical and medical uses, positioning Quantum BioPharma to capitalize on both consumer wellness and medical treatment markets. Additional information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM. The full press release detailing this announcement can be viewed at https://ibn.fm/yX7kt.
For investors and industry observers, this webinar represents an opportunity to understand how biotechnology innovations are transitioning from laboratory research to consumer products. The non-dilutive funding structure demonstrates innovative financial engineering in the biotech sector, while the product itself addresses a substantial market need with potential global health implications.
